REVELATION BIOSCIENCES, INC. (ticker: REVB) is an NASDAQ-listed pharmaceutical preparations company. DredgeCap's structured extraction of REVB's SEC filings surfaces 6 active risk signals, including 4 late-filing signals, 1 auditor-change signal, and 1 delisting/deregistration signal. REVB reported no tagged revenue in revenue and -$3.01M for the period ending 2026-03-31, with operating cash flow of -$3.21M. Cash and equivalents stood at $14.11M (up 281% year-over-year). Total assets of $15.04M exceed total liabilities of $2.06M. Each signal on this page is sourced verbatim from the underlying SEC filing. Use the tabs above to drill into auditor history, going-concern citations, dilution mechanics, cash runway, and the full risk-flag inventory.
REVB SEC Filings
Full cached SEC EDGAR filing history for REVB, grouped by form type and sorted newest-first within each group. 0 filings across 0 form types.
Filings sourced verbatim from SEC EDGAR submissions metadata. “Structured” links route to DredgeCap's per-filing renderer (XBRL-backed financials + cited highlights) when available; the EDGAR link always points to the canonical accession index on sec.gov.